Introduction {#section1-2040620718816698}
============

Acute myeloid leukemia (AML) is the most common form of acute leukemias in adults and, while pathogenetically heterogenous, it is typically caused by genetic events affecting hematopoietic progenitor or stem cells leading to the clonal proliferation of abnormally differentiated or undifferentiated myeloid cells.^[@bibr1-2040620718816698]^ Despite the identification of several genetic abnormalities underlying AML, the mainstay of AML therapy for fit patients for several decades has been intensive induction chemotherapy with anthracyclines and cytarabine, followed by consolidation chemotherapy or allogeneic hematopoietic stem cell transplantation.^[@bibr2-2040620718816698],[@bibr3-2040620718816698]^ However, intensive chemotherapy is generally only an option for younger and medically fit patients. Unfortunately, the majority of AML patients are older than 65 years with multiple comorbidities and are often ineligible for intensive chemotherapy with long-term survival rates of 10% or less.^[@bibr4-2040620718816698][@bibr5-2040620718816698]--[@bibr6-2040620718816698]^

Histone proteins provide a scaffold for storage of DNA within the nucleus of eukaryotic cells. The macromolecular complex of DNA and histone proteins is referred to as chromatin.^[@bibr7-2040620718816698]^ Chromatin modification altering interactions between DNA and histones is a highly dynamic process in cells affecting transcription, DNA repair and replication.^[@bibr7-2040620718816698]^ Epigenetics are most commonly defined as changes to the chromatin structure which can occur in the form of DNA methylation, histone modifications, and changes to higher-order chromatin structures that ultimately affect gene expression.^[@bibr8-2040620718816698],[@bibr9-2040620718816698]^ Epigenetic regulators can be broadly classified as 'writers' (e.g. DNA and histone methyltransferases), 'erasers' (e.g. histone deacetylase) or 'readers' (e.g. bromodomain-containing proteins).^[@bibr10-2040620718816698]^ The importance of epigenetics in cancer development has been well documented for several decades for both solid and hematologic malignancies.^[@bibr11-2040620718816698],[@bibr12-2040620718816698]^ Especially in AML, several specific mutations affecting epigenetic processes such as histone modification \[Enhancer of Zeste Homologue 2 (*EZH2*) and the additional sex combs-like gene (*ASXL1*)\], regulation of DNA methylation (*DNMT3A, TET2*) and enzymes regulating metabolism (*IDH1/2*) with epigenetic consequences have been identified as important players in pathogenesis of the disease and often with prognostic implications.^[@bibr2-2040620718816698],[@bibr10-2040620718816698],[@bibr13-2040620718816698][@bibr14-2040620718816698]--[@bibr15-2040620718816698]^

DNA methylation and DNA hydroxymethylation are key epigenetic pathways that have been linked to malignant transformation by inactivating tumor suppressor genes.^[@bibr7-2040620718816698],[@bibr16-2040620718816698]^ Mutations in genes affecting DNA methylation (e.g. *DNMT3A*) and demethylation (e.g. *TET2*) often cause silencing of target genes and are found in up to 22% and 23% of AML patients, respectively.^[@bibr17-2040620718816698],[@bibr18-2040620718816698]^ DNA methyltransferase (DNMT) inhibitors, which are also known as hypomethylating agents (HMAs), such as 5-azacytidine (5-AZA) and its analogue 5-aza-2'deoxycytidine (decitabine) have been used for over a decade in the treatment of patients with AML who are unfit for intensive induction chemotherapy and those with myelodysplastic syndromes (MDS). Trials have shown a significantly prolonged survival for treatment with HMAs compared with conventional care in MDS, with trends for better survival in AML, but the therapeutic effects of HMAs seen in clinical trials have been difficult to reproduce in the real-world setting and treatment failure is common.^[@bibr19-2040620718816698][@bibr20-2040620718816698][@bibr21-2040620718816698]--[@bibr22-2040620718816698]^

Besides DNA methylation, histone acetylation is a highly dynamic process of modifying gene transcription that is tightly regulated by the competing activity of histone lysine acetyltransferases and histone deacetylases (HDACs) with histone acetylation often leading to a more accessible chromatin structure that promotes gene transcription.^[@bibr7-2040620718816698]^ Mutations in other genes affecting histone modifying enzymes such as *EZH2* and *ASXL1* are found in up to 30% of AML patients.^[@bibr13-2040620718816698],[@bibr14-2040620718816698],[@bibr23-2040620718816698]^ HDAC inhibitors are a heterogenous group of molecules that increase histone acetylation which promote transcription of various genes mediating cell differentiation, cell cycle regulation and apoptosis.^[@bibr24-2040620718816698]^ Several studies using HDAC inhibitors as monotherapy for AML have yielded disappointing results with response rates less than 20%.^[@bibr24-2040620718816698]^

Overall, the therapeutic efficacy of HMAs and HDAC inhibitors are limited when used as single agents. Combination strategies of epigenetic therapy with either conventional chemotherapy, immunotherapy, or other forms of targeted therapies such as fms-related tyrosine kinase 3 (*FLT3*) inhibitors or the B-cell leukemia/lymphoma-2 (BCL-2) inhibitor venetoclax are currently in different stages of clinical testing and will be the focus of this review. [Figure **1**](#fig1-2040620718816698){ref-type="fig"} illustrates epigenetic mechanisms and potential therapeutic targets.

![Overview of epigenetic mechanisms and selected therapeutic interventions.\
Epigenetics refer to the modification of the chromatin structure without altering the base pair sequence of the DNA itself which is an essential process for regulating gene transcription and cell differentiation in both physiological conditions and malignant cell transformation. Epigenetic modifications can occur in the form of DNA methylation/hydroxymethylation, histone protein modifications (acetylation, methylation) and changes to higher-order chromatin structures. Methylation of CpG islands in the DNA generally suppress gene transcription and is mediated by DNA methyltransferases (DNMT). Alterations in DNA methylation have been linked to AML development and treatment with hypomethylating agents (e.g. azacitidine, decitabine) that inhibit DNMT has been successfully used in AML patients. On the other hand, DNA hydroxymethylation enhances gene transcription and is mediated by α-ketoglutarate-dependent enzymes such as TET2. *IDH1/2* mutations lead to the formation of the oncometabolite 2-hydroxyglutarate instead of α-ketoglutarate which blocks DNA hydroxymethylation. The action of mutated *IDH1/2* can be blocked by enasidenib and ivosidenib which restores function of enzymes orchestrating DNA hydroxymethylation. The DNA double-strand is stored in cells as a complex with histone proteins. Acetylation of histone proteins reduces the access of transcription factors to the DNA strand and thereby prevents gene transcription. Histone acetylation status is regulated by balancing the activity of histone deacetylases and histone acetylases which can be therapeutically targeted by bromodomain inhibitors and histone deacetylase (HDAC) inhibitors. Methylation and demethylation of histone proteins can occur at different sites of the histone molecule and is mediated by histone methyltransferases and histone demethylases. DOT1L is a histone H3K79 methyltransferase while EZH1/2 methylates histone H3K27 and both have both implicated in leukemogenesis and can be targeted by specific inhibitors. Histone demethylation can be blocked by LSD1 inhibitors.](10.1177_2040620718816698-fig1){#fig1-2040620718816698}

Combination of HMAs with other epigenetic therapy {#section2-2040620718816698}
=================================================

Combinations of HMAs and HDAC inhibitors {#section3-2040620718816698}
----------------------------------------

*In vitro* studies showed a synergistic effect of HDAC inhibitors and HMAs^[@bibr25-2040620718816698]^ leading to several clinical trials that combined HMAs and HDAC inhibitors in both AML and MDS ([Table 1](#table1-2040620718816698){ref-type="table"}).^[@bibr26-2040620718816698][@bibr27-2040620718816698][@bibr28-2040620718816698][@bibr29-2040620718816698][@bibr30-2040620718816698][@bibr31-2040620718816698][@bibr32-2040620718816698]--[@bibr33-2040620718816698]^ While most studies that showed synergistic effects have been single-arm studies, subsequent multi-arm studies comparing a combination of HMAs and HDAC inhibitors with HMA monotherapy have yielded disappointing results. Two large phase II trials combining 5-AZA with HDAC inhibitors (entinostat or vorinostat) failed to provide any survival benefit compared with 5-AZA monotherapy.^[@bibr28-2040620718816698],[@bibr30-2040620718816698],[@bibr31-2040620718816698]^ This might be due to higher rates of hematologic side effects in the combination therapy groups that led to earlier discontinuation of the treatment. As a molecular correlate of the lower response rate for the combination therapy, the reversal of promoter methylation was lower compared with 5-AZA monotherapy.^[@bibr30-2040620718816698]^ Additionally, the HDAC inhibitors used in these studies are a very heterogenous group in terms of their cellular targets and these pleotropic effects may have contributed to the excess toxicity seen in clinical trials leading to shortened treatment duration and insufficient drug exposure as potential explanations for the lack of clinical efficacy. Furthermore, reversal of histone acetylation may only be one of their mechanisms of action and additional biomarkers to predict response are needed.^[@bibr24-2040620718816698],[@bibr34-2040620718816698]^ Future challenges for this combination approach of HMAs and HDAC inhibitors that need to be addressed are optimization of the sequence and dose of drug administration as pharmacodynamic antagonism might have been an issue in these initial trials as well as the choice of the HDAC inhibitor itself with a need for more selective HDAC inhibitors. However, both entinostat which specifically targets histone deacetylases and the less selective drug vorinostat which is also acting on other protein deacetylases have yielded comparable results at least for MDS but this might not necessarily be true for AML as well.^[@bibr30-2040620718816698],[@bibr31-2040620718816698]^ It remains to be seen if the newer HDAC inhibitors such as belinostat, pracinostat, or panobinostat provide any additional benefit.^[@bibr34-2040620718816698],[@bibr35-2040620718816698]^ So far, data from a phase II study in elderly patients with AML ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT01912274) testing the pan-HDAC inhibitor pracinostat in combination with 5-AZA showed a median overall survival (OS) of 19.1 months and a composite complete remission (CRc) rate of 52% which exceeds historical data for 5-AZA alone^[@bibr36-2040620718816698]^ and has led to a phase III trial of 5-AZA ± pracinostat that is currently recruiting patients ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT03151408). In high-risk MDS patients, however, the combination of pracinostat and 5-AZA failed to improve outcomes which is potentially related to a higher rate of adverse events in the combination group that led to an earlier discontinuation of treatment.^[@bibr37-2040620718816698]^ Finally, guadecitabine (SGI-110), a novel decitabine analogue with a better bioavailability due to greater resistance to deamination, has yielded promising response rates in both elderly newly diagnosed AML patients and relapsed/refractory (RR)-AML making it an interesting target for combination therapy with HDAC inhibitors^[@bibr38-2040620718816698],[@bibr39-2040620718816698]^

###### 

Overview of selected clinical trials for combination of HMAs and HDAC inhibitors in AML treatment.

![](10.1177_2040620718816698-table1)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug combination                             Phase   *n*   Inclusion criteria                       Outcomes                                                                                                                                  Trial registration   Reference
  -------------------------------------------- ------- ----- ---------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- -------------------- ----------------------------------------------------------
  5-AZA + Vorinostat + gemtuzumab ozogamicin   I/II    52    RR-AML                                   CR: 23%, CRi: 19%                                                                                                                         NCT00895934          Walter and colleagues^[@bibr26-2040620718816698]^

  5-AZA + valproic acid + ATRA                 I/II    53    AML or HR-MDS                            ORR: 42% (pretreated), 52% (untreated);\                                                                                                  NCT00326170          Soriano and colleagues ^[@bibr27-2040620718816698]^
                                                                                                      median response duration: 26 weeks                                                                                                                             

  5-AZA ± entinostat                           II      47    Therapy-related AML or MDS               Median OS: 13 months (5-AZA alone) *versus* 6 months (combination)\                                                                       NCT00313586          Prebet and colleagues^[@bibr28-2040620718816698]^
                                                                                                      HN: 46% (5-AZA alone) *versus* 17% (combination)                                                                                                               

  5-AZA ± entinostat                           II      149   HR-MDS, AML                              HN: 32% (5-AZA alone) *versus* 27% (combination);\                                                                                        NCT00313586          Prebet and colleagues^[@bibr30-2040620718816698]^
                                                                                                      median OS: 18 months (5-AZA alone) *versus* 13 months (combination)                                                                                            

  5-AZA + phenylbutyrate                       II      29    HR-MDS, ND-AML, RR-AML                   ORR: 38% (4 CR)                                                                                                                                                Gore and colleagues^[@bibr33-2040620718816698]^

  Decitabine + vorinostat                      I       71    RR or ND-AML, IR- or HR-MDS              Response rate: concurrent *versus* sequential schedule in ND-AML (46% *versus* 14%), RR-AML (15% *versus* 0%) and MDS (60% *versus* 0%)   NCT00479232          Kirschbaum and colleagues^[@bibr29-2040620718816698]^

  Decitabine + valproic acid                   I/II    54    ND-AML, RR-AML, HR-MDS                   ORR: 22% (10 CR)\                                                                                                                         NCT00075010          Garcia-Manero and colleagues^[@bibr40-2040620718816698]^
                                                                                                      median OS: 15.3 months in responders *versus* 4.9 months in nonresponders;\                                                                                    
                                                                                                      untreated: ORR: 50%                                                                                                                                            

  Decitabine + valproic acid                   II      149   HR-MDS, ND-AML                           ORR: 51% (decitabine alone) *versus* 35% (combination);\                                                                                  NCT00414310          Issa and colleagues ^[@bibr32-2040620718816698]^
                                                                                                      median OS: 9.6 months (decitabine alone) *versus* 7.9 months (combination)                                                                                     

  Pracinostat + 5-AZA                          II      50    Age \> 65 years, ND-AML, secondary AML   CRc: 52%, median OS: 19.1 months                                                                                                          NCT01912274          Garcia-Manero and colleagues^[@bibr36-2040620718816698]^
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

5-AZA, 5-azacytidine; AML, acute myeloid leukemia; CR, complete remission; CRc, composite complete remission; Cri, complete remission with incomplete cell count recovery; HN, hematologic normalization; HR-MDS, high-risk myelodysplastic syndrome; IR-MDS, intermediate-risk myelodysplastic syndrome; NCT, [ClinicalTrials.gov](http://ClinicalTrials.gov) identifier; ND, new diagnosis; ORR, overall response rate; OS, overall survival; RR, relapsed/refractory.

Combination of HMAs and isocitrate dehydrogenase inhibitors {#section4-2040620718816698}
-----------------------------------------------------------

Methylation of cytosine-guanine dinucleotides (CpG) within the DNA is one of the key epigenetic mechanisms that regulate gene transcription and is mediated mainly by a tightly-controlled enzyme called DNA methyltransferase.^[@bibr11-2040620718816698],[@bibr41-2040620718816698]^ On the other hand, 5-hydroxymethylation of these cytosine residues by α-ketoglutarate-dependent enzymes such as ten eleven translocation (TET) DNA methylases leads to DNA demethylation.^[@bibr42-2040620718816698],[@bibr43-2040620718816698]^ Under physiological conditions, isocitrate dehydrogenase (IDH) catalyzes the conversion of isocitrate to α-ketoglutarate in the Krebs cycle. However, mutations in *IDH1* and *IDH2*, which are observed in 8% and 12% of AML patients, respectively, lead to the generation of the neometabolite 2-hydroxyglutarate (2-HG).^[@bibr44-2040620718816698]^ By competitively inhibiting α-ketoglutarate-dependent enzymes such as egg-laying-defective nine (EGL-9) prolyl hydroxylases, TET DNA methylases, and Jumonji C (JmjC) domain-containing histone demethylases, 2-HG causes DNA and histone hypermethylation leading to an impaired differentiation of myeloid precursor cells.^[@bibr45-2040620718816698],[@bibr46-2040620718816698]^ IDH inhibitors have been shown to lower levels of 2-HG and to restore differentiation of leukemic cells which ultimately led to overall response rates (ORRs) of around 40% in RR-AML patients and provided proof of principle that epigenetic therapies are a promising target in AML treatment.^[@bibr44-2040620718816698],[@bibr47-2040620718816698],[@bibr48-2040620718816698]^ However, potential nonepigenetic, leukemogenic effects of IDH mutations include impaired DNA repair by homologous recombination and impaired regulation of the transcription factor HIF1α which has been shown to inhibit hematopoietic stem cell and leukemic cell proliferation.^[@bibr49-2040620718816698][@bibr50-2040620718816698]--[@bibr51-2040620718816698]^ The effect of IDH inhibitors on these processes is still incompletely understood and the subject of ongoing research.

Since one of the mechanisms by which IDH mutations contribute to leukemogenesis is DNA hypermethylation, combination therapy of IDH inhibitors and HMAs seems to be a promising therapeutic strategy. Preclinical data have suggested a synergistic effect of enasidenib and 5-AZA leading to the initiation of a clinical phase I/II trial of enasidenib and 5-AZA ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT02677922) and a phase III trial of ivosidenib and 5-AZA for newly diagnosed AML patients ineligible for standard intensive chemotherapy ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT03173248).^[@bibr45-2040620718816698],[@bibr52-2040620718816698],[@bibr53-2040620718816698]^ While neither of these trials has been published in a peer-reviewed journal yet, data available in abstract form seem promising with an ORR of 73% \[*n* = 11; complete remission (CR): 50%\] in treatment-naïve, IDH1-mutated AML patients treated with ivosidenib and 5-AZA.^[@bibr52-2040620718816698]^ Preliminary data for the enasidenib + 5-AZA trial showed a 66% response rate (*n* = 6 patients; CR: 33%) in patients with newly diagnosed AML with nausea and hyperbilirubinemia being the most common adverse events.^[@bibr54-2040620718816698]^

Combination of HMAs and novel epigenetic therapies {#section5-2040620718816698}
--------------------------------------------------

So-called 'epigenetic readers' comprise a class of proteins that specifically bind to distinct DNA or histone modifications and constitute the third class of epigenetic regulators besides 'epigenetic writers' and 'epigenetic erasers'.^[@bibr10-2040620718816698]^ Rearrangements of the *MLL/KMT2A* gene are one of the first abnormalities in epigenetic regulators that has been linked to leukemogenesis and are associated with a poor prognosis.^[@bibr55-2040620718816698],[@bibr56-2040620718816698]^ Additionally, the *MLL* gene can fuse with several different other genes leading to the interaction with the histone H3K79 methyltransferase DOT1L causing the downstream transcriptional activation of various genes such as *HOXA9* and *MEIS* that have been linked to leukemogenesis.^[@bibr10-2040620718816698],[@bibr57-2040620718816698][@bibr58-2040620718816698]--[@bibr59-2040620718816698]^ Preclinical studies of small molecule inhibitors of DOT1L (EPZ004777, EPZ-5676) showed a high level of suppression of *HOX* expression leading to induction of cell differentiation and antileukemic activity.^[@bibr60-2040620718816698][@bibr61-2040620718816698]--[@bibr62-2040620718816698]^ A phase I human study of a DOT1L inhibitor (EPZ-5676; pinometostat) in 51 AML patients with *MLL* gene rearrangements showed a decreased level of H3K79 methylation and inhibition of *HOXA9* in some patients. However, the clinical benefit was very modest with formal clinical responses in only 2 out of 51 patients.^[@bibr63-2040620718816698]^ Potential explanations for these results include the heterogeneity of *MLL* fusion proteins with different levels of sensitivity to DOT1L inhibition and uncertainty about the optimal dose of pinometostat. As aberrant *HOX* expression is present in all AML cases with nucleophosmin (*NPM1*) gene mutations and DOT1L inhibition has also been shown to be effective in *DNMT3A*-mutated patients these patient subgroups might be particularly responsive to this approach.^[@bibr60-2040620718816698],[@bibr61-2040620718816698]^ The combination of pinometostat with HMAs such as 5-AZA has also been successfully tested in animal models and might be a feasible approach in humans as well.^[@bibr64-2040620718816698]^

*MLL* fusion proteins also interact with BET bromodomains which are epigenetic readers involved in the regulation of RNA polymerase II promoting the transcription of important regulatory genes such as *BCL2* and *c-MYC.*^[@bibr65-2040620718816698]^ Various BET inhibitors have shown strong *in vitro* antileukemic effects especially in *MLL*-mutated AML^[@bibr65-2040620718816698][@bibr66-2040620718816698][@bibr67-2040620718816698]--[@bibr68-2040620718816698]^ leading to several early-phase clinical trials testing BET inhibitors \[FT-1101 ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT02543879), MK-8628 ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT02698189), RO6870810 ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT02308761), GSK525762 ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT01943851), and INCB054329 ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT02431260)\] for use in human AML patients.^[@bibr69-2040620718816698]^ In a phase I trial using the BET inhibitor OTX015 ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT01713582), only 3 out of 41 pretreated patients (36 with AML) achieved a CR or CR with incomplete platelet count recovery (CRi)^[@bibr70-2040620718816698]^ suggesting that BET inhibitors alone might not be an adequate treatment strategy. Therefore, further studies are warranted to identify predictive biomarkers and to develop strategies for combination therapy of BET inhibitors with *FLT3*-inhibitors, HMAs, or HDAC inhibitors which have intriguing *in vitro* data.^[@bibr71-2040620718816698]^ Careful patient selection for future clinical trials is also warranted as preclinical studies have shown higher efficacy in *FLT3*-ITD-mutated and *NPM1*-mutated leukemia cells.^[@bibr72-2040620718816698],[@bibr73-2040620718816698]^

Similar to DNA methylation, histone methylation and demethylation are highly dynamic processes that can lead to either activation or repression of transcription depending on the specific location of the modified lysine residue.^[@bibr74-2040620718816698]^ Histone methylation is catalyzed by specific methyltransferases such as MLL1/2, DOT1L, and EZH1/2, while histone demethylation is mainly regulated by the activity of lysine-specific histone demethylase (LSD) 1 and LSD2.^[@bibr74-2040620718816698],[@bibr75-2040620718816698]^ Mutations in the involved genes and resulting overexpression of the encoded enzymes have been documented in both primary and secondary AML.^[@bibr74-2040620718816698]^ Pharmacological inhibition of LSD1 (ORY-1001, GSK2879552, IMG-7289) has been shown in animal models to induce differentiation of AML blasts and has been tested in phase I/II clinical trials ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifiers: NCT02177812, NCT02842827, EUDRACT no. 2013-002447-29).^[@bibr76-2040620718816698][@bibr77-2040620718816698][@bibr78-2040620718816698][@bibr79-2040620718816698]--[@bibr80-2040620718816698]^ While a phase I trial of the LSD1 inhibitor GSK2879552 has been stopped recently due to a negative risk-benefit assessment, preclinical data suggest synergistic effects of the combination of LSD1 inhibitors with the HDAC inhibitor panobinostat and all-trans-retinoic acid (ATRA).^[@bibr81-2040620718816698]^ LSD1 inhibition has been shown to increase HDAC inhibition and to block activity of the transcription factor c-Myc which can be further enhanced by addition of HDAC inhibitors.^[@bibr77-2040620718816698],[@bibr81-2040620718816698]^

EZH1 and EZH2 are epigenetic regulators that methylate histones (H3K27) and repress transcription of target genes. Dysfunction of EZH1/2 has been associated with unregulated self-renewal of leukemic stem cells and a poor prognosis of AML and MDS patients harboring these mutations.^[@bibr82-2040620718816698],[@bibr83-2040620718816698]^ Recent preclinical studies showed synergistic effects of EZH2 inhibition with the HMA decitabine and the HDAC inhibitor panobinostat.^[@bibr83-2040620718816698][@bibr84-2040620718816698]--[@bibr85-2040620718816698]^ The underlying mechanism is the enhanced effect on gene silencing by simultaneously preventing DNA methylation by HMAs or histone acetylation with HDAC inhibitors in combination with increasing the pro-transcriptional effect of histone methylation by EZH2 inhibition.^[@bibr83-2040620718816698]^ Additionally, trimethylation of histone H3K27 by EZH2 has been shown to mark genes for silencing by DNA methylation and is one of the mechanisms that has been linked with decitabine resistance.^[@bibr86-2040620718816698][@bibr87-2040620718816698]--[@bibr88-2040620718816698]^ However, neither of these combinations has yet been tested in clinical trials.

Combination of epigenetic therapy with conventional chemotherapy {#section6-2040620718816698}
================================================================

Combination of HMAs and conventional chemotherapy {#section7-2040620718816698}
-------------------------------------------------

Several *in vitro* studies have shown synergistic antileukemic effects of HMAs and anthracycline or cytarabine, which might be explained by the ability of 5-AZA to induce deoxycytidine kinase which phosphorylates cytarabine to its active phosphorylated form.^[@bibr89-2040620718816698][@bibr90-2040620718816698]--[@bibr91-2040620718816698]^ HMAs could also act as chemosensitizers that restore expression of tumor suppressor genes and thereby susceptibility to chemotherapy.^[@bibr92-2040620718816698]^ The combination of HMAs and cytarabine is especially interesting for older patients with AML who are ineligible for intensive chemotherapy as both agents when used alone have only shown moderate and transient response rates.^[@bibr93-2040620718816698],[@bibr94-2040620718816698]^ Initial phase I studies in AML patients tested the sequential application of HMAs followed by cytarabine and daunorubicin chemotherapy and showed CR rates of up to 83% in the absence of increased toxicity.^[@bibr92-2040620718816698],[@bibr95-2040620718816698],[@bibr96-2040620718816698]^ However, a subsequent larger phase II study in elderly AML patients comparing 5-AZA + cytarabine/daunorubicin ('7 + 3') induction chemotherapy with induction chemotherapy alone not only failed to show any survival benefit but rather led to increased adverse events.^[@bibr97-2040620718816698]^ Identification of molecular biomarkers as response predictors, fine-tuning of the treatment schedules (e.g. greater delay between 5-AZA and chemotherapy to decrease toxicity) and testing this combination in patients with lower cytogenetic risk might be valid approaches for future trials. There are several clinical trials currently active and enrolling patients ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifiers: NCT03417427, NCT01839240, NCT02275663) with the largest of such being a phase II study aiming to recruit 200 patients for epigenetic priming with 5-AZA or decitabine as a single agent prior to standard chemotherapy ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT03164057). [Table **2**](#table2-2040620718816698){ref-type="table"} provides an overview of selected published clinical trials combining epigenetic therapies with conventional chemotherapy.

###### 

Overview of selected clinical trials for combination of epigenetic therapies with conventional chemotherapy in AML treatment.

![](10.1177_2040620718816698-table2)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug combination                                                                                                                      Phase   *n*   Inclusion criteria                                    Outcomes                                                                                                                                  Trial registration     Reference
  ------------------------------------------------------------------------------------------------------------------------------------- ------- ----- ----------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- ---------------------- -----------------------------------------------------------
  Decitabine + (7 + 3) *versus* 7 + 3 alone                                                                                             I       30    ND-AML\<60 years with less-than-favorable karyotype   CR: 83%                                                                                                                                   NCT00538876            Scandura and colleagues^[@bibr92-2040620718816698]^

  5-AZA + (7+3)                                                                                                                         I       6     ND-AML \>60 years                                     Median OS: 266 days, no dose-limiting toxicity                                                                                            NCT00915252            Krug and colleagues^[@bibr95-2040620718816698]^

  Decitabine + low-dose idarubicin/cytarabine                                                                                           I/II    30    RR-AML, HR-MDS                                        CR: 67%                                                                                                                                   ChiCTR-OPC-15005771.   Ye and colleagues^[@bibr96-2040620718816698]^

  5-AZA + (7+3) *versus* 7 + 3 alone                                                                                                    II      214   ND-AML \>60 years                                     Median OS: 15 months (combination) *versus* 21 months 5-AZA + (7 + 3)                                                                     NCT00915252            Muller-Tidow and colleagues^[@bibr97-2040620718816698]^

  Decitabine + clofarabine + idarubicin + cytarabine; followed by consolidation of decitabine + clofarabine + idarubicin + cytarabine   II      54    RR-AML (⩽ salvage 2) \<65 years                       CR: 48% CR/CRi; 46% proceed to allo-HSCT                                                                                                  NCT01794702            Jain and colleagues^[@bibr98-2040620718816698]^

  vorinostat + idarubicin + cytarabine                                                                                                  II      75    HR-MDS, ND-AML \<65 years                             ORR: 85% (76% CR)                                                                                                                         NCT00656617            Garcia-Manero and colleagues^[@bibr99-2040620718816698]^

  Vorinostat + etoposide + cytarabine                                                                                                   I       21    RR-AML, RR-ALL, secondary AML, CML in blast crisis    Response rate: concurrent *versus* sequential schedule in ND-AML (46% *versus* 14%), RR-AML (15% *versus* 0%) and MDS (60% *versus* 0%)   NCT00357305            Gojo and colleagues^[@bibr100-2040620718816698]^

  panobinostat + idarubicin + cytarabine                                                                                                I/II    38    ND-AML \>65 years                                     CR: 64%;\                                                                                                                                 NCT00840346            Ocio and colleagues^[@bibr101-2040620718816698]^
                                                                                                                                                                                                            median OS: 17 months                                                                                                                                             

  7 + 3 *versus* idarubicin + high-dose cytarabine *versus* idarubicin + vorinostat                                                     III     738   ND-AML \<60 years                                     CR: 75--79% for all groups;\                                                                                                              NCT0180233             Garcia-Manero and colleagues^[@bibr102-2040620718816698]^
                                                                                                                                                                                                            better outcomes for 7 + 3 for favorable cytogenetics                                                                                                             
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

5-AZA, 5-azacitidine; AML, acute myeloid leukemia; CML, chronic myelogenous leukemia; CR, complete remission; CRi, complete remission with incomplete cell count recovery; HR-MDS, high-risk myelodysplastic syndrome; HSCT, hematopoietic stem cell transplant; NCT, [ClinicalTrials.gov](http://ClinicalTrials.gov) identifier; ND, new diagnosis; ORR, overall response rate; OS, overall survival; Ref, reference; RR, relapsed/refractory.

Combination of HDAC inhibitors and conventional chemotherapy {#section8-2040620718816698}
------------------------------------------------------------

While having only moderate antileukemic effects as single agents, HDAC inhibitors have shown synergistic activity in combination with various forms of conventional chemotherapy such as nucleoside analogues (cytarabine, fludarabine), anthracyclines, and topoisomerase inhibitors (etoposide).^[@bibr40-2040620718816698],[@bibr103-2040620718816698][@bibr104-2040620718816698]--[@bibr105-2040620718816698]^ The underlying mechanism for this synergy is not completely understood, but it is hypothesized that HDAC inhibitors promote a more open chromatin structure that might allow for better access of topoisomerase inhibitors to the DNA and therefore higher efficacy of chemotherapeutics.^[@bibr105-2040620718816698]^ Other studies investigating the synergy between doxorubicin and panobinostat implicated DNA double-strand breaks and activation of caspase-dependent apoptosis pathways in the antileukemic efficacy.^[@bibr104-2040620718816698]^

This concept has also been tested in various clinical trials. In a phase II trial of vorinostat in combination with cytarabine and idarubicin of 75 newly diagnosed AML or high-risk MDS patients ORRs were 85% and addition of vorinostat did not lead to an increase in toxicity.^[@bibr99-2040620718816698]^ Interestingly, 100% of patients with *FLT3*-ITD mutations responded and mutations in *NRF2* and *CYBB* were identified as biomarkers associated with a prolonged survival.^[@bibr99-2040620718816698]^ The SWOG 1203 study ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT0180233) was a phase III clinical trial comparing 7 + 3 induction chemotherapy, idarubicin + high-dose cytarabine, and idarubicin + vorinostat in 738 newly diagnosed AML patients younger than 60 years of age. CR rates were comparable for all treatment arms (75--79%) with significantly better outcomes for patients with favorable cytogenetics in the 7 + 3 arm.^[@bibr102-2040620718816698]^ However, in a cohort of RR-AML or secondary AML patients, the combination of vorinostat with etoposide and cytarabine yielded a response rate of 33%.^[@bibr100-2040620718816698]^ Another trial tested a combination of panobinostat with cytarabine and idarubicin in AML patients \>65 years of age.^[@bibr101-2040620718816698]^ Despite a reported longer relapse-free survival, addition of panobinostat in a subset of patients led to dose-limiting degrees of toxicity.^[@bibr101-2040620718816698]^ Future challenges in this field include defining the optimal timing and combination partners as concomitant application of vorinostat and cytarabine had antagonistic effects while sequential administration led to synergy.^[@bibr100-2040620718816698]^

Combination of epigenetic therapy with targeted therapy {#section9-2040620718816698}
=======================================================

Combination of epigenetic therapy and venetoclax {#section10-2040620718816698}
------------------------------------------------

B-cell leukemia/lymphoma-2 (BCL-2) is an anti-apoptotic protein that inhibits cell death by blocking permeability of the mitochondrial outer membrane.^[@bibr106-2040620718816698]^ Though first identified in follicular lymphoma, BCL-2 is also overexpressed in other hematologic malignancies including AML and has been implicated in leukemia stem cell survival.^[@bibr107-2040620718816698],[@bibr108-2040620718816698]^ BCL-2 activity is regulated by a group of small molecules known as BH3-mimetics that bind to and inhibit the BH3 domain of BCL-2 proteins which releases proapoptotic factors from their BCL-2 binding site and triggers apoptosis.^[@bibr109-2040620718816698]^

Venetoclax (ABT-199) is an oral, highly-specific BCL-2 inhibitor which is United States Food and Drug Administration (US FDA)-approved for the treatment of chronic lymphocytic leukemia.^[@bibr110-2040620718816698],[@bibr111-2040620718816698]^ Venetoclax has recently been shown to be modestly effective as a single agent in the treatment of RR-AML or newly diagnosed AML patients who are ineligible for intensive chemotherapy.^[@bibr112-2040620718816698]^ However, early-phase clinical data have shown both an impressive synergistic effect and acceptable safety profile of venetoclax in combination with HMAs ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT02203773; composite CR: 61%, median OS: 17.5 months) or low-dose cytarabine ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT02287233; CR/CRi: 62%; median OS: 11.4 months) in the frontline setting in elderly AML patients ineligible for intensive chemotherapy.^[@bibr107-2040620718816698],[@bibr113-2040620718816698],[@bibr114-2040620718816698]^ Acknowledging the remarkable response rates that exceed historical outcomes with 5-AZA alone (composite CR: 28%, median OS: 10.4 months),^[@bibr115-2040620718816698]^ the combination of 5-AZA and venetoclax received breakthrough designation by the US FDA and is currently tested in a phase III clinical trial against 5-AZA monotherapy.^[@bibr106-2040620718816698]^ A similar trial of cytarabine in combination with venetoclax is also currently recruiting ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT03069352).

The combination of venetoclax and either HMAs or low-dose cytarabine appears to have activity in the AML salvage therapy setting based on data which reported objective response rates of 21% and a median OS of 3.0 months.^[@bibr107-2040620718816698]^ While these numbers seem modest at a first glance, it must be kept in mind that 94% of these patients had been pretreated and 41% of the patients had failed ⩾3 previous lines of therapy.^[@bibr112-2040620718816698]^

On a molecular basis this synergy can be explained by the fact that resistance to venetoclax is mediated by the antiapoptotic proteins BCL-XL and MCL1 which can be overcome by combination therapy with HMAs, daunorubicin or cytarabine.^[@bibr116-2040620718816698],[@bibr117-2040620718816698]^ On the other hand, resistance of leukemic blasts to chemotherapy has been linked to overexpression of BCL-2.^[@bibr118-2040620718816698]^ Therefore, combining venetoclax with HMAs targets resistance mechanisms that have hampered monotherapy with either of these agents and seems to make this combination highly effective.^[@bibr107-2040620718816698]^ Of note, subgroup analysis has shown that patients with *IDH1/2* mutations have higher response rates to venetoclax monotherapy which is due to the fact that IDH-mutant AML cells depend on BCL-2 for survival.^[@bibr112-2040620718816698],[@bibr119-2040620718816698],[@bibr120-2040620718816698]^

Combination of epigenetic therapy and *FLT3* inhibitors {#section11-2040620718816698}
-------------------------------------------------------

Addition of the multikinase inhibitor midostaurin to intensive induction chemotherapy was recently shown to yield a higher response rate than chemotherapy alone leading to its US FDA-approval for the treatment of *FLT3*-mutated AML in conjunction with chemotherapy.^[@bibr121-2040620718816698]^ One potential explanation for treatment failure in *FLT3*-mutated AML with *FLT3* inhibitors is the persistence of leukemic stem cells in a protective bone marrow compartment; animal models have demonstrated that this barrier can be overcome by the combination of *FLT3* inhibitors with HMAs.^[@bibr122-2040620718816698],[@bibr123-2040620718816698]^ Another study suggested that one mechanism of resistance to *FLT3* inhibitors is higher expression of *FLT3* ligand following chemotherapy which could block the action of tyrosine kinase inhibitors on *FLT3* kinase.^[@bibr124-2040620718816698]^ Given that the expression of *FLT3* ligand is lower in patients treated with HMAs, early-phase clinical trials combining HMAs with the *FLT3* inhibitors sorafenib^[@bibr125-2040620718816698]^ and midostaurin,^[@bibr126-2040620718816698][@bibr127-2040620718816698]--[@bibr128-2040620718816698]^ especially in elderly and RR-AML patients, have been conducted. Despite one study reporting that the addition of midostaurin to HMAs did not provide any additional benefit,^[@bibr128-2040620718816698]^ other studies have reported ORRs of about 25% and a median OS of 22 weeks, which is longer compared with historical data from 5-AZA or midostaurin as single agents.^[@bibr126-2040620718816698],[@bibr127-2040620718816698],[@bibr129-2040620718816698],[@bibr130-2040620718816698]^

In addition to midostaurin, several more specific *FLT3* inhibitors such as quizartinib and gilteritinib have been developed and are currently being tested in combination with HMAs ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifiers: NCT03661307, NCT01892371, NCT02752035). To date, only abstract data from the combination of 5-AZA and quizartinib have been published. In a phase I/II study of 37 patients with both newly diagnosed and previously treated AML, MDS or chronic myelomonocytic leukemia with *FLT3-ITD* mutation the combination of 5-AZA and quizartinib showed an overall response (CR, CRi, CRp, partial remission (PR)) rate of 76% with a median OS of 13.4 months.^[@bibr131-2040620718816698]^ An overview of selected completed studies of HMAs in combination with several forms of targeted therapies is provided in [Table 3](#table3-2040620718816698){ref-type="table"}.

###### 

Overview of selected clinical trials for combination of hypomethylating agents and targeted therapies in AML treatment.

![](10.1177_2040620718816698-table3)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug combination                                  Phase   *n*   Inclusion criteria                 Outcomes                                             Trial registration   Reference
  ------------------------------------------------- ------- ----- ---------------------------------- ---------------------------------------------------- -------------------- ---------------------------------------------------------
  Decitabine ± posaconazole or 5-AZA + venetoclax   I       47    ND-AML\<65                         CR/CRi: 61%;\                                        NCT02203773          DiNardo and colleagues^[@bibr107-2040620718816698]^
                                                                                                     median OS: 17.5 months                                                    

  5-AZA + sorafenib                                 II      37    ND-AML \>60 years, RR-AML          CR/CRi: 43%; median OS: 6.2 months\                  NCT01254890          Ravandi and colleagues^[@bibr125-2040620718816698]^
                                                                                                     ND-AML: CR/CRi: 67%\                                                      
                                                                                                     RR-AML: CR/CRi: 33%                                                       

  5-AZA + midostaurin                               I/II    54    RR-AML, ND-AML, HR-MDS, s-AML      ORR: 26%\                                            NCT01202877          Strati and colleagues^[@bibr127-2040620718816698]^
                                                                                                     Median OS: 22 weeks                                                       

  Decitabine + midostaurin                          I       16    ND-AML \>60 years, RR-AML          CR/CRi: 25%, median response duration: 107 days      NCT01130662          Williams and colleagues^[@bibr126-2040620718816698]^

  5-AZA + Midostaurin                               I/II    17    ND-AML \>70 years, RR-AML, s-AML   ORR: 18%\                                            NCT01093573          Cooper and colleagues^[@bibr128-2040620718816698]^
                                                                                                     Median OS: 6 months\                                                      
                                                                                                     No difference between ND-AML and RR-AML                                   

  Quizartinib + 5-AZA or LDAC                       I/II    59    ND and RR-AML, MDS, CMML           \(1\) Untreated: ORR: 92%, median OS: 18.6 months\   NCT01892371          Swaminathan and colleagues^[@bibr131-2040620718816698]^
                                                                                                     (2) Pretreated: ORR: 73%; median OS: 11.25 months                         

  5-AZA + nivolumab                                 IB/II   51    RR-AML                             CR/CRi: 18%\                                         NCT02397720          Daver and colleagues^[@bibr132-2040620718816698]^
                                                                                                     Median OS: 9.3 months                                                     
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

5-AZA, azacitidine; AML, acute myeloid leukemia; CMML, chronic myelomonocytic leukemia; CR, complete remission; Cri, complete remission with incomplete cell count recovery; HR-MDS, high-risk myelodysplastic syndrome; LDAC, low-dose cytarabine; NCT, [ClinicalTrials.gov](http://ClinicalTrials.gov) identifier; ND, new diagnosis; ORR, overall response rate; OS, overall survival; Ref, reference; RR, relapsed/refractory; s-AML, secondary AML.

Combination of epigenetic therapy and immunotherapy {#section12-2040620718816698}
---------------------------------------------------

Evasion of immunosurveillance by epigenetic silencing of genes involved in immune recognition and effector T-cell function is an essential feature of cancer cells and contributes to the immunosuppressive tumor microenvironment.^[@bibr133-2040620718816698]^ HMAs have been shown to increase the expression of leukemia-associated antigens such as NY-ESO-1 and MAGE-A that can potentially trigger an antileukemia immune response.^[@bibr134-2040620718816698][@bibr135-2040620718816698][@bibr136-2040620718816698][@bibr137-2040620718816698]--[@bibr138-2040620718816698]^ Additionally, they contribute to immune system activation by increasing the expression of major histocompatibility complex (MHC)-I and co-stimulatory molecules (ICAM1, CD80, CD86).^[@bibr135-2040620718816698],[@bibr138-2040620718816698],[@bibr139-2040620718816698]^ However, at the same time HMAs are also hampering antitumor immune response by upregulating the expression of immune checkpoint molecules such as programmed cell death (PD)-1/programmed death ligand (PD-L)1 and cytotoxic T-lymphocyte-associated protein (CTLA)-4 which may contribute to treatment failure with HMAs.^[@bibr140-2040620718816698][@bibr141-2040620718816698]--[@bibr142-2040620718816698]^ However, the increased expression of PD-1/PD-L1 with HMA treatment may lead to a greater susceptibility of cancer cells to treatment with PD-1/PD-L1 inhibitors. Preclinical experiments have shown that pretreatment with 5-AZA led to an enhanced response to treatment with immunotherapeutics such as CTLA-4 inhibitors.^[@bibr143-2040620718816698]^ Studies in non-small cell lung cancer patients have provided additional proof of principle that combing HMAs with PD-1/PD-L1 inhibitors sensitized patients to treatment with PD-1 inhibitors.

These findings have inspired various clinical trials that combine HMAs with various PD-1 inhibitors \[nivolumab ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT02397720), and pembrolizumab ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT02845297)\], PD-L1 inhibitors \[durvalumab ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT02775903), and atezolizumab ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT02508870)\], or the CTLA-4 inhibitor ipilimumab ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifiers: NCT02890329, NCT02397720). One study demonstrated a 33% ORR (22% CR/CRi) and median OS of 6.3 months in RR-AML patients treated with nivolumab and 5-AZA combination therapy (*n* = 35), which appears to be better compared with historic controls of 5-AZA alone and the effect seemed to be long lasting.^[@bibr132-2040620718816698]^ However, 11% of patients developed grade 3/4 immune-mediated adverse events that were controlled with corticosteroids except for one death from grade 4 pneumonitis.^[@bibr132-2040620718816698]^ Of note, a clinical trial of 5-AZA with atezolizumab ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT02508870) has been discontinued due to safety concerns. Future studies to address the safety profile of checkpoint inhibitors are therefore warranted prior to their broader clinical application. There are some early data that suggest a different efficacy of PD-1 *versus* CTLA-4 inhibition in myeloid neoplasms making studies investigating the combination of different immune checkpoint inhibitors with HMAs an interesting area of research and such trials are currently ongoing \[combination of nivolumab and ipilimumab with 5-AZA ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT02397720)\].^[@bibr140-2040620718816698]^ Immune checkpoint inhibitors could also be applied to control minimal residual disease as preclinical data suggest that immune checkpoint pathways contribute to immune system evasion and that these dormant leukemia cells are susceptible to T-cell-mediated cytolysis.^[@bibr144-2040620718816698]^

Future directions {#section13-2040620718816698}
=================

Our understanding of the epigenetic processes underlying AML is still incomplete. With further improvement in and wider availability of diagnostic techniques such as next-generation sequencing, an increasing number of mutations affecting epigenetic regulators is being discovered, but their precise impact on AML development and their suitability as therapeutic targets remains to be elucidated in preclinical experiments. However, identification of these mutations has already led to the development and approval of drugs that specifically target these mutations which has paved the way to a more individualized treatment approach for AML patients. Nevertheless, several important questions remain to be answered.

One of the major challenges remaining is the appropriate selection of patients who are most likely to benefit from an intervention. While targeted therapies such as IDH inhibition with ivosidenib and enasidenib only work in patients with IDH mutations, predicting treatment response to HMAs or HDAC inhibitors is difficult. Methylation of CpG islands has been suggested to be a biomarker predicting response to HMAs.^[@bibr145-2040620718816698]^ However, subsequent studies showed that methylation status is dynamic while patients are undergoing treatment and that it depends rather on the methylation status of certain individual genes than on the overall CpG methylation status.^[@bibr146-2040620718816698],[@bibr147-2040620718816698]^ Additionally, epigenetic therapies such as DOT1L and BET inhibition can be successful even if the target gene is not mutated at all which questions the utility of simple gene mutation testing and underlines the need for broader drug sensitivity testing.^[@bibr13-2040620718816698]^ The combination of different mutations can predict treatment response as well which is seen in the higher response rate of patients with concomitant IDH mutations who are treated with venetoclax. Further studies are warranted to guide appropriate drug selection.^[@bibr112-2040620718816698]^

Various studies have shown that targeting a single genetic mutation such as *FLT3* is not sufficient to control or eradicate cancer. Basic research has shown the synergy of different therapeutics in combination can target leukemia cell escape mechanisms which have hampered therapeutic success with single agent therapies. The most promising approaches so far appear to be the use of HMAs in combination with immune checkpoint inhibitors and venetoclax. Additionally, it remains to be seen if more specific epigenetic therapies such as EZH2 or DOT1L inhibitors will increase the response rates compared with 'older' HMAs or HDAC inhibitors.

Finally, preleukemic hematopoietic stem cells already harbor some mutations in genes that are involved in epigenetic changes such as DNA methylation and histone modification.^[@bibr148-2040620718816698]^ Interestingly, these progenitor cells can survive induction chemotherapy and have been linked to disease relapse.^[@bibr149-2040620718816698]^ As some of the earliest mutations occurring during the transformation of normal HSCs to leukemia clones are seen in *IDH1/2* and *DNMT3A*^[@bibr148-2040620718816698]^ targeting these mutations either early in the disease course or to maintain minimal residual disease following chemotherapy might be an interesting target that is already being explored in clinical trials (e.g. [ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT01757535).^[@bibr150-2040620718816698]^

Conclusion {#section14-2040620718816698}
==========

Epigenetic therapy in AML is still in its infancy but is a rapidly evolving and highly promising field. While early forms of epigenetic therapies like the HMAs 5-AZA and decitabine have shown modest effects, more targeted therapies such as IDH inhibitors have shown a better response and survival rates in appropriately selected patients. Combination therapies of either epigenetic therapies with conventional chemotherapy, different forms of epigenetic therapies, or epigenetic therapies with immunotherapy promise even higher success rates even in elderly and RR-AML patients as they target cell proliferation at different levels. However, further research is needed to identify biomarkers that predict response to therapy and guide drug selection for individual patients.
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